Imbalanced Frequencies of Th17 and Treg Cells in Acute Coronary Syndromes Are Mediated by IL-6-STAT3 Signaling

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ma, Yanhui ^a   Yuan, Xiangliang ^a   Deng, Lin ^a   Xu, Weiping ^a   Zheng, Yingxia ^a   Yue, Chaoyan ^a   Zhang, Guanghui ^a   Xie, Fang ^a   Yang, Yuan H ^b   Gantier, Michael P ^b   Liu, JunPing ^c   Xu, Dakang ^b,c   Shen, Lisong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MONASH UNIVERSITY   (Australia)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TROPONIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL FEATURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TH17 CELL; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84883110332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072804     Document Type: Article

References (51)

1. Robertson AK, Hansson GK, (2006) T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 26: 2421-2432.
2. Stockinger B, Veldhoen M, Martin B, (2007) Th17 T cells: linking innate and adaptive immunity. Semin Immunol 19: 353-361.
3. Wilke CM, Bishop K, Fox D, Zou W, (2001) Deciphering the role of Th17 cells in human disease. Trends Immunol 32: 603-611.
4. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, et al. (2009) Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119: 1424-1432.
5. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, et al. (2008) The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 127: 89-97.
6. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, et al. (2009) CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 131: 109-118.
7. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
8. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M, (2005) A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 115: 1953-1962.
9. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM, (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688.
10. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F, (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942-949.
11. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al. (2006) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950-957.
12. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
13. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, et al. (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487.
14. Manel N, Unutmaz D, Littman DR, (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9: 641-649.
15. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, et al. (2008) A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 9: 650-657.
16. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, et al. (2008) IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454: 350-352.
17. Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, et al. (2009) In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci U S A 106: 6232-6237.
18. Mangan PR, Harrington LE, O′Quinn DB, Helms WS, Bullard DC, et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234.
19. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23): 2999-3054.
20. Gensini GG, (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51(3): 606.
21. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, et al. (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332: 687-696.
22. Yuan XL, Chen L, Li MX, Dong P, Xue J, et al. (2010) Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol 134: 277-288.
23. Ndrepepa G, Tada T, Fusaro M, Cassese S, King L, et al. (2012) Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease. Clin Res Cardiol 101(12): 1003-11.
24. Breen EC, Reynolds SM, Cox C, Jacobson LP, Magpantay L, et al. (2011) Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol 18: 1229-1242.
25. Dong C, (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8: 337-348.
26. Taga T, Kishimoto T, (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819.
27. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133.
28. Maseri A, Fuster Va, (2003) Is There a Vulnerable Plaque? Circulation 107: 2068-2071.
29. Liang J, Zheng Z, Wang M, Han L, Peng J, et al. (2009) Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. J Int Med Res 37: 862-866.
30. von Vietinghoff S, Ley K, (2010) Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 21: 463-469.
31. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, et al. (2010) Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121: 1746-1755.
32. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, et al. (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94(5): 874-7.
33. Ng SB, Tan YH, Guy GR, (1994) Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 269: 19021-1902.
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH, (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101(15): 1767-72.
35. Becker KL, Ed. (2001) Principles and practice of endocrinology and metabolism. Philadelphia: JB Lippincott Co. 2077-2086p.
36. Korn T, Bettelli E, Oukka M, Kuchroo VK, (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
37. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B, (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
38. Liuzzo G, Trotta F, Pedicino D, (2013) Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J 34(8): 556-9.
39. Li Q, Wang Y, Chen K, Zhou Q, Wei W, et al. (2010) The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome. Biochem Biophys Res Commun 394: 836-842.
40. Zhao Z, Wu Y, Cheng M, Ji Y, Yang X, et al. (2011) Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 217: 518-524.
41. Liu Z, Lu F, Pan H, Zhao Y, Wang S, et al. (2012) Correlation of peripheral Th17 cells and Th17-associated cytokines to the severity of carotid artery plaque and its clinical implication. Atherosclerosis 221: 232-41.
42. Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, et al. (2013) Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 34: 570-577.
43. Ammirati E, Cannistraci CV, Cristell NA, Vecchio V, Palini AG, et al. (2012) Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction. Circ Res 26 111(10): 1336-48.
44. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium (2012) Hingorani AD, Casas JP, (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 31 379(9822): 1214-24.
45. IL6R Genetics Consortium Emerging Risk Factors Collaboration (2012) Sarwar N, Butterworth AS, Freitag DF, Gregson J, et al. (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 31 379(9822): 1205-13.
46. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1 102(7): 1369-76.
47. Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, et al. (2005) Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 33(1):89-97;discussion 242-3.
48. Jones SA, Scheller J, Rose-John S, (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121(9): 3375-83.
49. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, et al. (2008) Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 58: 3710-3719.
50. Feldmann M, Williams RO, Paleolog E, (2010) What have we learnt from targeted anti-TNF therapy? Ann Rheum Dis 69Suppl 1: i97-99.
51. Kopf M, Bachmann MF, Marsland BJ, (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9: 703-718.